Evercore ISI Group Reaffirms Outperform Rating for Privia Health Group, Increases Price Target to $30

Written by Emily J. Thompson, Senior Investment Analyst

PRVA+0.44%

Source: Benzinga

Updated: Nov 07 2025

0mins

Source: Benzinga

Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, providing real-time market intelligence to help them succeed.
Exclusive Content: Subscribers gain access to exclusive stories and insights generated by Benzinga reporters, enhancing their trading strategies.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and strategies for better trading outcomes.
Market Winning Tools: The platform is designed to equip traders with the tools and information necessary to make informed decisions in the stock market.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy PRVA?" and start using high-conviction signals backed by rigorous historical data.

Sign up today to access powerful investing tools and make smarter, data-driven decisions.

PRVA

$22.87+Infinity%1D

Analyst Views on PRVA

Wall Street analysts forecast PRVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRVA is 30.40 USD with a low forecast of 23.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

12 Analyst Rating

11 Buy

1 Hold

0 Sell

Strong Buy

Current: 22.770

Low

23.00

Averages

30.40

High

34.00

Current: 22.770

Low

23.00

Averages

30.40

High

34.00

RBC Capital

initiated

$31

2026-01-09

Reason

RBC Capital

Price Target

$31

AI Analysis

2026-01-09

initiated

Reason

RBC Capital resumed coverage of Privia Health with an Outperform rating and $31 price target. Privia is seen as a leading play in physician enablement, a high-growth area at the intersection of technology and healthcare utilization, the analyst tells investors in a research note. Growth is expected to continue as Privia expands its physician network and fee-based collections, leveraging its payor-agnostic model to outpace a market focused on "margin over growth" while value-based care adoption matures through 2026-2027, the firm adds.

JPMorgan

Lisa Gill

maintain

$32 -> $33

2025-11-13

Reason

JPMorgan

Lisa Gill

Price Target

$32 -> $33

2025-11-13

maintain

Reason

JPMorgan analyst Lisa Gill raised the firm's price target on Privia Health to $33 from $32 and keeps an Overweight rating on the shares. The firm updated the company's estimates post earnings.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for PRVA

Unlock Now

About PRVA

Privia Health Group, Inc. is a technology-driven, national physician-enablement company. The Company collaborates with medical groups, health plans and health systems. It enhances physician practices, improves patient experiences and doctors for delivering care in both in-person and virtual care settings. Its Privia Platform is powered by the Privia Technology Solution, an end-to-end, cloud-based technology solution that integrates both Privia-developed and third-party applications into an interface and workflow that manages all aspects of its Privia Providers provision of healthcare services. Privia Platform optimizes provider workflow across the full continuum of reimbursement arrangements. The Company provides management services to each Medical Group though a local management services organization, which provides Medical Groups with access to value-based care (VBC) opportunities either directly or through Privia-owned accountable care organizations.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

GET FREE REAL TIME NOTIFICATIONS

Stock Monitor for PRVA?

Get Started Free

FREE STOCK RECOMMENDATIONS DAILY

Stock Bullish Tomorrow

Get Started Free

70% BACKTESTED ACCURACY!

Should I Buy PRVA?

Get Started Free

Top News

Evercore ISI Group Reaffirms Outperform Rating for Privia Health Group, Increases Price Target to $30

Trade with 70% Backtested Accuracy

Analyst Views on PRVA

About PRVA

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

ArcBest Q4 Earnings Report Analysis

Opendoor Stock Set for Fourth Consecutive Monthly Decline

BMO Capital Begins Coverage of Privia Health Group with Outperform Rating and Sets Price Target at $30

Evercore ISI Group Reaffirms Outperform Rating for Privia Health Group, Increases Price Target to $30

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch